Anti-Glutamic Acid Decarboxylase 65/67 antibody produced in rabbit

Description

• General description: GAD 65 has been identified as an autoantigen in insulin dependent diabetes mellitus (IDDM) and stiff-man syndrome (SMS).
• Specificity: Reacts specifically with GAD 65 and GAD 67 isoforms from brain.
• Immunogen: synthetic peptide corresponding to the C-terminal region of human GAD 67 (amino acids 579-594). The sequence is identical in human GAD 65 (amino acids 570-585), in rat, mouse, and pig GAD 65, in rat, pig, and cat GAD 67, and is highly conserved in GAD 67 of mouse origin (single amino acid substitution).
• Application: Anti-GAD 65/67 may be used for the detection and localization of GAD 65/67 isoforms by immunofluorescence and immunohistochemistry in rat retinal cells, human subthalamus neurons, and pancreatic β-cells of rat. The minimum working dilution that may be used is 1:10000. Detection by immunoblotting may be possible in brain cells of monkey, human, rat and gecko. at a minimum working dilution of 1:1000.
• Biochem/physiol Actions: Glutamic acid decarboxylase (GAD) is the key enzyme that catalyses the conversion of L-glutamate to γ-aminobutyric acid (GABA). GABA is a principal inhibitory neurotransmitter and a paracrine signal molecule in pancreatic islet cells. GAD 65 has been identified as an autoantigen in insulin dependent diabetes mellitus (IDDM) and stiff-man syndrome (SMS).
• Physical form: Solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide.
• Disclaimer: Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.